Swayambhu Biologics Profile
Key Indicators
- Authorised Capital ₹ 1.00 Cr
as on 02-01-2025
- Paid Up Capital ₹ 9.90 M
as on 02-01-2025
- Company Age 14 Year, 1 Month
- Last Filing with ROC 31 Mar 2022
- Revenue %
(FY 2022)
- Profit 9.99%
(FY 2022)
- Ebitda 12.97%
(FY 2022)
- Net Worth -565.13%
(FY 2022)
- Total Assets 0.03%
(FY 2022)
About Swayambhu Biologics
The Company is engaged in the Life Sciences Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2022. It's a company limited by shares with an authorized capital of Rs 1.00 Cr and a paid-up capital of Rs 9.90 M, as per Ministry of Corporate Affairs (MCA) records.
Madam Govardhan and Kowsalya Vijaybhashkaran serve as directors at the Company.
- CIN/LLPIN
U01400TN2010PTC078266
- Company No.
078266
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
30 Nov 2010
- Date of AGM
29 Sep 2022
- Date of Balance Sheet
31 Mar 2022
- Listing Status
Unlisted
- ROC Code
Roc Chennai
Industry
Company Details
- Location
Chennai, Tamil Nadu, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Swayambhu Biologics Private Limited offer?
Swayambhu Biologics Private Limited offers a wide range of products and services, including Natural Carotenoids, Herbal Capsules, Spirulina Capsule, Pharmaceutical Medicine, Lycopene.
Who are the key members and board of directors at Swayambhu Biologics?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Madam Govardhan  | Additional Director | 07-Nov-2022 | Current |
| Kowsalya Vijaybhashkaran | Additional Director | 07-Nov-2022 | Current |
Financial Performance of Swayambhu Biologics.
Swayambhu Biologics Private Limited, for the financial year ended 2022, experienced no change in revenue, with a 0% increase. The company also saw a slight improvement in profitability, with a 9.99% increase in profit. The company's net worth observed a substantial decline by a decrease of 565.13%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Swayambhu Biologics?
In 2021, Swayambhu Biologics had a public holding of 1.59%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Jagathi Agrowtechs Private LimitedActive 13 years 8 monthsMadam Govardhan and Kowsalya Vijaybhashkaran are mutual person
- Gruha Promoters And Constructions Private LimitedActive 2 years 6 months
Madam Govardhan is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Swayambhu Biologics?
Unlock and access historical data on people associated with Swayambhu Biologics, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Swayambhu Biologics, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Swayambhu Biologics's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
